Combining Src inhibitors with compounds targeting other key regulators or signaling pathways, such as BI2536 (PLK1 inhibitor), KX2-361 (Tubulin inhibitor) and JSI-124 (STAT3 inhibitor), has achieved notable consequences for glioma treatment in vitro and in vivo [23,24,25,26]. The gene discussed is SRC; the disease is glioma.